Anti-telomerase immune response predicts disease progression in chronic lymphocytic leukemia
Human telomerase reverse transcriptase (hTERT) is broadly expressed in many cancers. High hTERT expression have been described in chronic lymphocytic leukemia (CLL). Here we investigated the relationship between anti-hTERT immunity and disease progression in 49 CLL patients. Anti-hTERT T cell respon...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-12-01
|
| Series: | Clinical Immunology Communications |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772613421000093 |
| _version_ | 1818744837333057536 |
|---|---|
| author | Claire Germain Julie Garibal Valérie Doppler Fanny Baran-Marszak Florence Cymbalista Julien Caumartin Pierre Langlade-Demoyen Maria Wehbe Thierry Huet |
| author_facet | Claire Germain Julie Garibal Valérie Doppler Fanny Baran-Marszak Florence Cymbalista Julien Caumartin Pierre Langlade-Demoyen Maria Wehbe Thierry Huet |
| author_sort | Claire Germain |
| collection | DOAJ |
| description | Human telomerase reverse transcriptase (hTERT) is broadly expressed in many cancers. High hTERT expression have been described in chronic lymphocytic leukemia (CLL). Here we investigated the relationship between anti-hTERT immunity and disease progression in 49 CLL patients. Anti-hTERT T cell responses were evaluated by IFNγ-ELISpot. Complementary flow cytometry analyses were performed, and data were analyzed in regards of the treatment received by CLL patients afterward and disease progression. Anti-hTERT responses were more frequently observed in non-progressive watch and wait patients, and in progressive patients scheduled to receive ibrutinib, as compared to patients scheduled to receive other types of treatment. In vitro, addition of the anti-PD-1 antibody nivolumab increased anti-hTERT responses. Importantly, Kaplan Meier analyses showed significantly longer progression-free survival in patients with anti-hTERT immune responses at diagnosis as compared to non-responder patients. Our results show that anti-hTERT T cell responses represent a new potential biomarker predictive of CLL clinical outcome. |
| first_indexed | 2024-12-18T02:50:39Z |
| format | Article |
| id | doaj.art-20171fe6484d48c7bf25ab7d867a845a |
| institution | Directory Open Access Journal |
| issn | 2772-6134 |
| language | English |
| last_indexed | 2024-12-18T02:50:39Z |
| publishDate | 2021-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Clinical Immunology Communications |
| spelling | doaj.art-20171fe6484d48c7bf25ab7d867a845a2022-12-21T21:23:27ZengElsevierClinical Immunology Communications2772-61342021-12-0113544Anti-telomerase immune response predicts disease progression in chronic lymphocytic leukemiaClaire Germain0Julie Garibal1Valérie Doppler2Fanny Baran-Marszak3Florence Cymbalista4Julien Caumartin5Pierre Langlade-Demoyen6Maria Wehbe7Thierry Huet8Invectys, 12 rue Jean-Antoine de Baïf, Biopark, 75013 Paris, FranceInvectys, 12 rue Jean-Antoine de Baïf, Biopark, 75013 Paris, FranceInvectys, 12 rue Jean-Antoine de Baïf, Biopark, 75013 Paris, FranceService d'Hématologie Biologique, Hôpital Avicenne, 125 Rue de Stalingrad, 93000 Bobigny, FranceService d'Hématologie Biologique, Hôpital Avicenne, 125 Rue de Stalingrad, 93000 Bobigny, FranceInvectys, 12 rue Jean-Antoine de Baïf, Biopark, 75013 Paris, FranceInvectys, 12 rue Jean-Antoine de Baïf, Biopark, 75013 Paris, FranceInvectys, 12 rue Jean-Antoine de Baïf, Biopark, 75013 Paris, France; Corresponding author at: Preclinical Department, Invectys, 12 rue Jean-Antoine de Baïf, Biopark, 75013 Paris, France.Invectys, 12 rue Jean-Antoine de Baïf, Biopark, 75013 Paris, FranceHuman telomerase reverse transcriptase (hTERT) is broadly expressed in many cancers. High hTERT expression have been described in chronic lymphocytic leukemia (CLL). Here we investigated the relationship between anti-hTERT immunity and disease progression in 49 CLL patients. Anti-hTERT T cell responses were evaluated by IFNγ-ELISpot. Complementary flow cytometry analyses were performed, and data were analyzed in regards of the treatment received by CLL patients afterward and disease progression. Anti-hTERT responses were more frequently observed in non-progressive watch and wait patients, and in progressive patients scheduled to receive ibrutinib, as compared to patients scheduled to receive other types of treatment. In vitro, addition of the anti-PD-1 antibody nivolumab increased anti-hTERT responses. Importantly, Kaplan Meier analyses showed significantly longer progression-free survival in patients with anti-hTERT immune responses at diagnosis as compared to non-responder patients. Our results show that anti-hTERT T cell responses represent a new potential biomarker predictive of CLL clinical outcome.http://www.sciencedirect.com/science/article/pii/S2772613421000093Chronic lymphocytic leukemiaTelomeraseT cellsPFS, IGHV, PD-1 |
| spellingShingle | Claire Germain Julie Garibal Valérie Doppler Fanny Baran-Marszak Florence Cymbalista Julien Caumartin Pierre Langlade-Demoyen Maria Wehbe Thierry Huet Anti-telomerase immune response predicts disease progression in chronic lymphocytic leukemia Clinical Immunology Communications Chronic lymphocytic leukemia Telomerase T cells PFS, IGHV, PD-1 |
| title | Anti-telomerase immune response predicts disease progression in chronic lymphocytic leukemia |
| title_full | Anti-telomerase immune response predicts disease progression in chronic lymphocytic leukemia |
| title_fullStr | Anti-telomerase immune response predicts disease progression in chronic lymphocytic leukemia |
| title_full_unstemmed | Anti-telomerase immune response predicts disease progression in chronic lymphocytic leukemia |
| title_short | Anti-telomerase immune response predicts disease progression in chronic lymphocytic leukemia |
| title_sort | anti telomerase immune response predicts disease progression in chronic lymphocytic leukemia |
| topic | Chronic lymphocytic leukemia Telomerase T cells PFS, IGHV, PD-1 |
| url | http://www.sciencedirect.com/science/article/pii/S2772613421000093 |
| work_keys_str_mv | AT clairegermain antitelomeraseimmuneresponsepredictsdiseaseprogressioninchroniclymphocyticleukemia AT juliegaribal antitelomeraseimmuneresponsepredictsdiseaseprogressioninchroniclymphocyticleukemia AT valeriedoppler antitelomeraseimmuneresponsepredictsdiseaseprogressioninchroniclymphocyticleukemia AT fannybaranmarszak antitelomeraseimmuneresponsepredictsdiseaseprogressioninchroniclymphocyticleukemia AT florencecymbalista antitelomeraseimmuneresponsepredictsdiseaseprogressioninchroniclymphocyticleukemia AT juliencaumartin antitelomeraseimmuneresponsepredictsdiseaseprogressioninchroniclymphocyticleukemia AT pierrelangladedemoyen antitelomeraseimmuneresponsepredictsdiseaseprogressioninchroniclymphocyticleukemia AT mariawehbe antitelomeraseimmuneresponsepredictsdiseaseprogressioninchroniclymphocyticleukemia AT thierryhuet antitelomeraseimmuneresponsepredictsdiseaseprogressioninchroniclymphocyticleukemia |